



2215 Yukon St .
Vancouver, BC
Canada, V5Y 0A1
T 1. 604.559.9005
abcellera.com

NEWS RELEASE

AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023

10/31/2023

VANCOUVER, British Columbia--(BUSINESS WIRE)-- **AbCellera** (Nasdaq: ABCL) today announced that executives from the Company will present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 4:30 p.m. Greenwich Mean Time (8:30 a.m. Pacific Time).

A live audio webcast of the presentation may be accessed through a link that will be posted on **AbCellera's Investor Relations website**. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera's engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit **www.abcellera.com**.

Inquiries

Media: Jessica Yingling, Ph.D.; **media@abcellera.com**, +1(236)521-6774

Business Development: Murray McCutcheon, Ph.D.; **bd@abcellera.com**, +1(604)559-9005

Investor Relations: Josephine Hellschlienger, Ph.D.; **ir@abcellera.com**, +1(778)729-9116

Source: AbCellera Biologics Inc.